Company: ANTX
Filing Date: 2025-03-25
Form Type: S-8
Source: 0000950170-25-044432
Chunk: 0

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-03-25
Form: S-8
Chunk 0
---
<div align='center'>As filed with the Securities and Exchange Commission on March 25, 2025</div>

Registration No. 333-

<div align='center'>___________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

___________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________________________________________________________________________

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

________________________________________________________________________________________

AN2 Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

________________________________________________________________________________________</div>

| Delaware                        |     | 82-0606654         |
| (State or other jurisdiction of 
 incorporation or organization)  |     | -I.R.S. Employer   
 Identification No. |

<div align='center'>1800 El Camino Real, Suite D

Menlo Park, California 94027

(Address of principal executive offices) (Zip code)

AN2 Therapeutics, Inc. 2022 Equity Incentive Plan

AN2 Therapeutics, Inc. 2022 Employee Stock Purchase Plan

(Full titles of the plans)

Eric Easom

Chief Executive Officer

AN2 Therapeutics, Inc.

1800 El Camino Real, Suite D

Menlo Park, California 94027

(650) 331-9090

(Name and address of agent for service) (Telephone number, including area code, of agent for service)

________________________________________________________________________________________

Copies to:</div>

| Kathleen M. Wells            
 Richard Kim                  
 Latham & Watkins LLP         
 140 Scott Drive              
 Menlo Park, California 94025 
 (650) 328-4600               |     | Lucy O. DayAN2 Therapeutics, Inc.                                      
 1800 El Camino Real, Suite DMenlo Park, California 94027(650) 331-9090 |

<div align='center'>________________________________________________________________________________________</div>

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

| Large accelerated filer |     | ☐ |     | Accelerated filer         |     | ☐ |
|